We propose to leverage the multicenter international BVMC HHT recruitment network and the BVMC HHT database, in the next funding cycle, to characterize the risk of intracranial hemorrhage (ICH) in HHT patients with BAVMs and subgroups. To do so, we propose to expand the cohort of HHT BAVM patients, building on our established multicenter HHT BAVM database, the largest such cohort in the world. By doubling the cohort size and extending natural history follow-up, in Aim 1 we will increase precision of ICH rates in HHT BAVM patients overall, as well as subgroups of patients, and bring these estimates into a relevant range for clinical decision making.
In Aim 2, we propose to investigate genetic modifiers of HHT and BAVM phenotypes, building on preliminary evidence from the first BVMC cycle. We demonstrated that the ALK1 variant IVS3-35A>G is associated with HHT disease severity (presence of any organ AVMs), particularly in patients with an ENG mutation. We therefore postulate a second-hit or trans-heterozygosity hypothesis, which states that in addition to the disease-causing mutation, further reduction of function in the TGFBeta/BMP9 signaling pathway exacerbates HHT phenotypes. To test this hypothesis, we will evaluate common variants in pathway genes for their association with (1) "any AVMs" and (2) BAVM risk in HHT patients and explore associations with ICH risk and other HHT severity phenotypes. We will utilize the initial BVMC HHT cohort (n=800, 200 BAVM) for discovery and the new second-cycle HHT cohort of 800 for replication.
Aim 3 is an exploratory aim, in which we plan to study vessel wall inflammation in BAVMs and ICH, using vessel wall imaging and tissue review for inflammatory cells and mediators. Project 3 participants will be recruited through 12 HHT Centers of Excellence, as well as the Patient Support Organization, HHT Foundation International (HHTFI). The HHT investigator group will continue to work closely with the HHTFI, as well as with the DMCC, leveraging the established DMCC web-based portal, data collection and management protocols in place. The BVMC HHT Project will continue to provide a much-needed and valuable resource for the clinical neurovascular community for the study of BAVMs in HHT.

Public Health Relevance

Hereditary Hemorrhagic Telangiectasia (HHT) is a rare genetic disorder characterized by arteriovenous malformations (AVMs) in the brain, lung, and liver. Clinical care for people with brain AVMs (BAVMs) remains a challenge, with devastating intracranial hemorrhage (ICH) an ongoing reality. Quantitative information about the risks of ICH from BAVMs in HHT patients is needed to guide clinical decision-making and therapeutic trials in these patients;Project 3 will characterize these risks, as well as their determinants.

Agency
National Institute of Health (NIH)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
2U54NS065705-06
Application #
8913453
Study Section
Special Emphasis Panel (ZTR1)
Program Officer
Moy, Claudia S
Project Start
Project End
Budget Start
Budget End
Support Year
6
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Walcott, Brian P; Choudhri, Omar; Lawton, Michael T (2016) Brainstem cavernous malformations: Natural history versus surgical management. J Clin Neurosci 32:164-5
Choquet, Hélène; Trapani, Eliana; Goitre, Luca et al. (2016) Cytochrome P450 and matrix metalloproteinase genetic modifiers of disease severity in Cerebral Cavernous Malformation type 1. Free Radic Biol Med 92:100-9
Kavanaugh, Brian; Sreenivasan, Aditya; Bachur, Catherine et al. (2016) [Formula: see text]Intellectual and adaptive functioning in Sturge-Weber Syndrome. Child Neuropsychol 22:635-48
Merkel, Peter A; Manion, Michele; Gopal-Srivastava, Rashmi et al. (2016) The partnership of patient advocacy groups and clinical investigators in the rare diseases clinical research network. Orphanet J Rare Dis 11:66
Walcott, Brian P; Winkler, Ethan A; Rouleau, Guy A et al. (2016) Molecular, Cellular, and Genetic Determinants of Sporadic Brain Arteriovenous Malformations. Neurosurgery 63 Suppl 1:37-42
Kaplan, Emma H; Kossoff, Eric H; Bachur, Catherine D et al. (2016) Anticonvulsant Efficacy in Sturge-Weber Syndrome. Pediatr Neurol 58:31-6
Krings, T; Kim, H; Power, S et al. (2015) Neurovascular manifestations in hereditary hemorrhagic telangiectasia: imaging features and genotype-phenotype correlations. AJNR Am J Neuroradiol 36:863-70
Golden, Michael; Saeidi, Saba; Liem, Benny et al. (2015) Sensitivity of patients with familial cerebral cavernous malformations to therapeutic radiation. J Med Imaging Radiat Oncol 59:134-6
Choquet, H; Pawlikowska, L; Lawton, M T et al. (2015) Genetics of cerebral cavernous malformations: current status and future prospects. J Neurosurg Sci 59:211-20
Comi, Anne M (2015) Sturge-Weber syndrome. Handb Clin Neurol 132:157-68

Showing the most recent 10 out of 34 publications